Triple inhaled therapy reduces moderate, severe COPD exacerbations: ETHOS

Triple inhaled therapy with twice-daily budesonide, at two doses, glycopyrrolate and formoterol reduced the rate of moderate or severe COPD exacerbations compared with two dual-combination therapies, according to data from the ETHOS trial. “For the first time, triple therapy with half the dose of inhaled corticosteroid was shown to have greater efficacy than higher-dose inhaled